NCT00880269

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

A Phase II Study of Oral Single Agent Panobinostat in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.

Conditions

• Refractory Leukemia
• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
DRUG	Panobinostat/LBH589

Timeline

• Start date: 2009-08-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2009-04-13
• Last updated: 2017-02-23
• Results posted: 2016-09-09

Locations

40 sites across 12 countries: United States, Australia, Belgium, France, Germany, Italy, Peru, South Korea, Spain, Switzerland, Turkey (Türkiye), United Kingdom